Chemotherapy Induced Neutropenia (CIN) - Drug Pipeline Landscape, 2023

Published Feb 02, 2023

Length 90 Pages

SKU # GIS17762184

Description

Chemotherapy Induced Neutropenia is a very common side effect of cancer treatment in which the number of neutrophils in the blood drops below a healthy level.

Chemotherapy Induced Neutropenia main causes are age, co-morbidities, and time course of therapy.

Chemotherapy Induced Neutropenia main symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, and abdominal pain.

Doctors will diagnose neutropenia with a type of blood test includes complete blood cell count and also by the test that is conducted regularly during treatment to monitor how well the body is handling chemotherapy.

Chemotherapy-induced neutropenia is treated by lifestyle modification and drugs like granulocyte colony-stimulating factors.

Report Highlights

Global Insight Service’s, "Chemotherapy Induced Neutropenia (CIN) - Drug Pipeline Landscape, 2023" report provides an overview of the Chemotherapy Induced Neutropenia (CIN) pipeline drugs. This report covers detailed insights on Chemotherapy Induced Neutropenia (CIN) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chemotherapy Induced Neutropenia (CIN) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy

Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.

Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.

Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.

Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

List of Tables

List of Figures

1. Introduction

1.1 Chemotherapy Induced Neutropenia – Pipeline Drugs, 2023-Coverage

2. Disease Overview – Chemotherapy Induced Neutropenia

2.1 Causes

2.2 Signs and Symptoms

2.3 Diagnosis

2.4 Disease Management

3. Chemotherapy Induced Neutropenia – Pipeline Drugs Development - Overview

3.1 Comparative Analysis by Stage of Development

3.2 Number of Products under Development by Companies, 2023

3.3 Products under Development by Companies, 2023

4. Assessment of Therapeutics

4.1 Assessment by Target

4.2 Assessment by Mechanism of Action

4.3 Assessment by Molecule Type

4.3 Assessment by Route of Administration

5. Drug Profiles

5.1 Clinical Stage Drugs – Pre-Registration

5.1.1 F-627

5.2 Clinical Stage Drugs – Phase III

5.2.1 MW 0511

5.2.2 Pegfilgrastim

5.2.3 Plinabulin + Pegfilgrastim

5.2.4 YPEG-rhG-CSF

5.3 Clinical Stage Drugs – Phase I

5.3.1 Myelo001

5.3.2 rHSA-GCSF

5.4 Clinical Stage Drugs – Phase I

5.4.1 ALRN-6924

5.4.2 BP13

5.4.3 BP14

5.4.4 Rolvedon

5.4.5 TX04

5.5 Clinical Stage Drugs – Preclinical

5.5.1 BBT-007

5.5.2 BBT-015

5.5.3 Filgrastim

5.5.4 Pegfilgrastim Biosimilar

5.5.5 PEG-GCSF

5.5.6 UB-853

6. Key Regulatory Designations

7. Key Deals

8. Key Upcoming Milestones

9. Key Companies Involved

9.1 Aileron Therapeutics

9.2 Beyond Spring Pharmaceuticals Inc.

9.3 Biocure Technology Inc

9.4 Bolder Bio Technology Inc

9.5 Curateq Bilogics Private Limited

9.6 EVIVE Biotechnology

9.7 Hanmi Pharmaceutical

9.8 Mabwell (Shanghai) Bioscience Co Ltd

9.9 Myelo Therapeutics GmbH

9.10 PharmaEssentia Corporation

9.11 Tanvex BioPharma Inc

9.12 Tianjin SinoBiotech Ltd.

9.13 UBI Pharma Inc

9.14 USV Limited

9.15 Xiamen Amoytop Biotech Co Ltd

10. Dormant Drugs

10.1 Inactive Drugs

10.2 Discontinued Drugs

11. Appendix

List of Tables

Table 1.1 Number of Products Under Development for Chemotherapy Induced Neutropenia

Table 1.2 Number of Products Under Development by Companies

Table 1.3 Products Under Development by Companies

Table 1.4 Products by Targets

Table 1.5 Products by Mechanism of Action

Table 1.6 Products by Molecule Type

Table 1.7 Products by Route of Administration

Table 2.1 Clinical Trial Details - 8MW0511/Mabwell (Shanghai) Bioscience Co Ltd

Table 2.2 Clinical Trial Details - F-627/EVIVE Biotechnology

Table 2.3 Clinical Trial Details - Plinabulin/Beyond Spring Pharmaceuticals Inc

Table 2.4 Clinical Trial Details - YPEG-rhG-CSF/Xiamen Amoytop Biotech Co Ltd

Table 2.5 Clinical Trial Details - Myelo001/Myelo Therapeutics GmbH

Table 2.6 Clinical Trial Details - rHSA-GCSF/Tianjin SinoBiotech Ltd

Table 2.7 Clinical Trial Details - ALRN-6924/Aileron Therapeutics

Table 2.8 Clinical Trial Details - BP13/Curateq Bilogics Private Limited

Table 2.9 Clinical Trial Details - BP14/Curateq Bilogics Private Limited

Table 2.10 Clinical Trial Details - Rolvedon/Hanmi Pharmaceutical

Table 3.1 Regulatory Designations

Table 4.1 Inactive Drugs

Table 4.2 Discontinued Drugs

List of Figures

Figure 1.1 Number of Products under Development for Chemotherapy Induced Neutropenia, 2023

Figure 1.2 Products by Top 5 Targets and Stage of Development for Chemotherapy Induced Neutropenia, 2023

Figure 1.3 Products by Top 5 Mechanism of Action for Chemotherapy Induced Neutropenia, 2023

Figure 1.4 Products by Top 5 Molecule Type for Chemotherapy Induced Neutropenia, 2023

Figure 1.5 Products by Top 5 Route of Administration for Chemotherapy Induced Neutropenia, 2023

Pricing

Currency Rates

Single User Email from Publisher $2,000
Global Site License Email from Publisher $3,000

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now